APA (7th ed.) Citation

K, S., L, W., N, C., M, F., R, Y., D, A., . . . M, P. (2025). IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials. Drug safety, 48(8), 855. https://doi.org/10.1007/s40264-025-01540-x

Chicago Style (17th ed.) Citation

K, Steplewski, et al. "IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials." Drug Safety 48, no. 8 (2025): 855. https://doi.org/10.1007/s40264-025-01540-x.

MLA (9th ed.) Citation

K, Steplewski, et al. "IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials." Drug Safety, vol. 48, no. 8, 2025, p. 855, https://doi.org/10.1007/s40264-025-01540-x.